Royalty Pharma Reports 13% Royalty Growth and $295M Q1 Profit
RPRX•Royalty Pharma posted a first-quarter profit of $295 million, delivering a 13% increase in recurring royalty receipts and adjusted EPS of $1.30, topping the $1.22 consensus. The company rolled out a global R&D co-funding model targeting a $1 trillion market opportunity and forecast portfolio operating costs at 5.5–6.5% of receipts.
1. Q1 Financial Results
Royalty Pharma recorded a first-quarter profit of $295 million and adjusted earnings per share of $1.30, surpassing the $1.22 analyst consensus. Revenue reached $631 million with adjusted revenue of $925 million, and full-year revenue guidance was set at $3.33–3.45 billion dollars.
2. Recurring Royalty Growth Drivers
Recurring royalty receipts grew 13% year-over-year, driven by a diversified portfolio and the absorption of the Promacta loss of exclusivity. Franchise strength in cystic fibrosis therapies and recent launches including Voranigo and Evrysdi were primary contributors to revenue growth.
3. Strategic R&D Co-Funding Model
Management outlined a strategic pivot toward co-funding R&D with global biopharma partners, aiming to access a $1 trillion development market. This 'win-win' approach allows partners to share risk and Royalty Pharma to gain early exposure to high-priority programs through contra R&D accounting.
4. Cost Management and Outlook
Internalization of management functions is expected to drive cost savings, with operating and professional expenses forecast at 5.5–6.5% of portfolio receipts in 2026. These efficiencies support margin expansion as the company scales its co-funding initiatives.
